Wednesday, January 28, 2015

Tuesday Features

In conversation with Allen Krantz

In conversation with Allen Krantz

Dr. Allen Krantz As the founder, president and CEO of Advanced Proteome Therapeutics (TSX-V:APC; Frankfurt:OE8), Dr. Allen Krantz has successfully transitioned a career in academia to the biotech sector. From 1968 to 1974, he was a member of the Faculty of Chemistry at the State University of New York at Stony Brook and from 1974 to 1981 he held appointments... [Read more of this feature]


EndyMed expands sales effort in U.S.

EndyMed expands sales effort in U.S.

After five years of selling its skin rejuvenation devices to medical professionals through a distributor, EndyMed Medical (TASE:ENDY) has launched a U.S.-based direct sales operation through subsidiary, EndyMed USA. “During the second half of 2014, we expanded the sales force team to cover all major markets in the U.S. and significantly increased... [Read more of this feature]


Harvard Apparatus to file IND for regenerated trachea trial

Harvard Apparatus to file IND for regenerated trachea trial

Harvard Apparatus Regenerative Technology (NASDAQ:HART) plans to file an IND later this year for a pivotal trial of the world’s first regenerated trachea transplant in patients facing life-threatening trachea trauma and cancer. David Green “Our InBreathAirway Transplant System has been successful in six human compassionate cases and because we have... [Read more of this feature]


More Posts From Tuesday Features

Briefs

Enlivex gets EMA orphan drug status for ApoCell

Enlivex gets EMA orphan drug status for ApoCell

Enlivex Therapeutics, a member of the Hadasit Bio-Holdings group (TASE:HDST; OTCQB:HDASY), has received orphan drug status from the European Medicines Agency (EMA) for its lead product candidate, ApoCell, for the prevention of Graft-versus-host Disease (GvHD). ApoCell already has orphan drug designation from the FDA. The company plans to initiate a... [Read more of this brief]


TearLab names Raymond Kong as VP sales

TearLab names Raymond Kong as VP sales

TearLab (NASDAQ:TEAR; TSX:TLB) has appointed Raymond Kong to its senior management team as VP of Sales. He succeeds Duane Morrison, who will shift his focus to major accounts and doctor networks in the newly created position of VP of business development. Most recently, Mr. Kong served as general manager for Alcon Laboratories’ Indonesia business,... [Read more of this brief]


Provectus gets Chinese process patent allowance

Provectus gets Chinese process patent allowance

Provectus Biopharmaceuticals (NYSE MKT:PVCT) has received notification of allowance from the Chinese Patent Office for its application protecting the synthetic process used to produce the small molecule Rose Bengal, the active pharmaceutical ingredient (API) in PV-10, the company’s lead oncology drug candidate. The pending Chinese patent covers... [Read more of this brief]


Actinium submits pre-IND meeting request to FDA

Actinium submits pre-IND meeting request to FDA

Actinium Pharmaceuticals (NYSE MKT:ATNM) has submitted a request for a pre-IND meeting to the FDA for the company’s Iomab-B drug candidate currently undergoing final preparations to start a pivotal Phase 3 trial in mid-2015. The initial indication for Iomab-B is conditioning for bone marrow transplant in older relapsed and refractory acute myeloid... [Read more of this brief]


Knight in financing pact with Synergy Strips

Knight in financing pact with Synergy Strips

Knight Therapeutics (TSX:GUD) has entered into a $6-million senior secured debt financing agreement with Synergy Strips, a U.S. company focused on the health and wellness sector. The secured loan will finance Synergy’s acquisition of the FOCUSfactor brand, the No. 1 brain health supplement in the U.S. The loan will bear interest at 15% a year,... [Read more of this brief]


More Posts From Briefs
Email Newsletters with Constant Contact
Google+